Selank
Aliases: TP-7 · Thr-Lys-Pro-Arg-Pro-Gly-Pro
Last verified: 2026-09-23
The short version
Selank has an unusual profile: a Russian-registered drug for anxiety (in some former Soviet states), with small clinical trials suggesting a mild anxiolytic effect, but without robust Western evidence standards. Mechanistically it is linked to GABAergic and dopaminergic systems, and nootropic claims rest on animal work. Western regulators do not consider it a proven therapy.
Identity & type
- Molecular type
- analog
- Sequence / structure
- Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 aa)
- Molecular weight
- ~752 Da
- Origin
- Heptapeptide analog of tuftsin (a natural immunomodulatory tetrapeptide), developed in Russia.
Mechanism of action
Modulates the GABAergic system (allosterically), alters IL-6 and BDNF expression, stabilizes enkephalins (inhibits their degradation).
not confirmed in humans
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Nasal 0.15% solution: 2–3 drops per nostril 1–3× daily (270–450 mcg/day).
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Nasal 0.15% solution: 2–3 drops per nostril 1–3× daily (270–450 mcg/day). Most commonly reported: reduced anxiety and a "quieter mind" without sedation, better stress tolerance; effects mild but clean. Nasal, fast-acting (15–30 min).
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Most commonly reported: reduced anxiety and a "quieter mind" without sedation, better stress tolerance; effects mild but clean. Nasal, fast-acting (15–30 min).
Protocol — official vs community
Official / label
Russian-approved nasal preparation (0.15% solution): 2–3 drops per nostril 2–3× daily, course-based.
- 01Flat intranasal dosing
Duration: 10–14 day courses per domestic labeling.
Tuftsin-analogue anxiolytic peptide with domestic approval and thin export evidence.
Community (anecdotal)
0.15–0.3% nasal spray 1–3× daily; subcutaneous use appears but nasal is the standard.
- Cycle:
- 2 weeks on, 2+ weeks off.
- Break:
- 2+ weeks between courses.
Frequently paired with Semax (focus + calm) — the community's flagship cognitive stack.
Human evidence
Small Russian clinical trials in generalized anxiety; no large randomized trials to Western standards.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Rare mild adverse effects; profile appears favorablecharacterized
- Lack of long-term Western safety datacharacterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Replication of effects in large rigorous trials
Frequently asked questions
References
- Russian clinical studies of selank (placebo-controlled, published in Russian journals)